Why Farbe Firma is the Leading Injectable Manufacturer in Micronesia
Why Farbe Firma is the Leading Injectable Manufacturer in Micronesia
Last Updated: 21 September 2026
TL;DR: The Federated States of Micronesia is not the unregulated market its size suggests. Two Acts signed on 21 June 2022 created a national Pharmaceutical Unit, an Approved Medicines List and a licensing regime, and a 2025 package added three assessment routes keyed to named authorities. India's CDSCO is on none of those lists. One clause of the same guideline admits authorities at WHO Maturity Level 3 for medicines or vaccines, which reaches CDSCO, and it sits against an annex that does not. We print both readings and choose neither.
Key Takeaways
The governing instruments are the FSM Safe Pharmaceutical Act of 2022 and the FSM Pharmaceutical Import Control Act of 2022, signed on 21 June 2022 with no deferred commencement. They add new chapters to Titles 41 and 54 of the FSM Code. The consolidated code published online stops at 2001 and does not show them, so citing it as evidence that the FSM has no medicines law is citing a stale document.
At the border, Customs may release a pharmaceutical only to a licensed FSM Establishment, and only where the product either sits on the Approved Medicines List from a competent jurisdiction or holds a product registration from the national Pharmaceutical Unit. A WHO-format Certificate of a Pharmaceutical Product forms part of the same check at the port.
Three assessment routes exist, at rising cost and review time. The fastest keys to a closed list of reference authorities. The middle route names four national authorities and requires a PIC/S-inspected site. The full route asks for an ICH CTD dossier, registration in three other countries and sample testing at the applicant's expense. CDSCO is named on none of those lists, and India is not a PIC/S participating authority.
Medicines regulation is national: the regulations state that they apply to all four FSM states, though Yap retains its own labelling law. The Global Fund's 2026 eligibility list marks the FSM eligible for HIV and tuberculosis, so the donor channel is operative rather than empty, even though no current grant could be located.
Introduction: Why an Injectable Manufacturer in Micronesia Cannot Work From the Published Code
The first thing to establish about the Federated States of Micronesia is that the easily searchable version of its law is out of date. The consolidated FSM Code available online is updated only to 2001, and the medicines chapters that now govern this market were inserted in 2022. A buyer who reads that code, finds no pharmaceutical chapter and concludes the FSM operates no medicines control has made a documentary error.
What changed is substantial. The two 2022 Acts created a national Pharmaceutical Unit, an Approved Medicines List, an establishment licensing regime and an offence structure with penalties attached. A regulation-and-guideline package followed, adding forms, fees, annexes of recognised authorities and indicative timelines. The national health department's notice asks affected parties to treat the regulations as effective from early March 2025 unless they learn otherwise, a careful formulation repeated here as written.
What the Rules Ask of an Injectable Manufacturer in Micronesia, Layer by Layer
Keep the three layers apart, because they fail in different ways. At the importer layer, a licensed FSM Establishment is mandatory and a foreign manufacturer may not be the importer of record; the application form contemplates that establishment acting as local technical representative. At the product layer, the medicine must be on the Approved Medicines List or separately registered. At the site layer, the regulator's inspection power survives the paperwork and is priced in the fee schedule, so a certificate never waives inspection.
The three routes are where an Indian file meets friction. The fastest keys to a closed annex that does not name CDSCO. The middle route names four national authorities, none Indian, and requires a PIC/S-inspected site, which India's regulator cannot deliver because it is not a PIC/S participating authority. The full route is open on its face but asks for a complete ICH CTD dossier, registration in three other countries, independent sample testing and a GMP certificate from an FSM-recognised authority. That last limb is the hard one.
Quality Systems Behind Every Sterile Injectable Batch
Farbe Firma manufactures under WHO-GMP certification in Gujarat, India, with ISO Class 5 aseptic filling zones under continuous environmental monitoring. Batch release rests on analytical work rather than assertion: HPLC and GC for assay and related substances, Karl Fischer for water content, LAL for bacterial endotoxins, plus sterility, particulate matter and container-closure integrity testing. Each batch carries a certificate of analysis naming the method, the specification and the result.
Stability is scoped to the destination rather than a default. The FSM sits in a hot, humid climatic zone, and a dossier built on temperate-zone data invites a deficiency letter. Our programme runs to ICH Q1A and Q1B under tropical conditions, with photostability data where the molecule warrants it. Dossiers are compiled in CTD or ACTD format so the same body of work can be re-cut for a national register, a donor exercise or a tender annex without being rebuilt.
Why Farbe Firma is the Trusted Injectable Manufacturer in Micronesia for Global Buyers
Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries. What we bring to a market shaped like the FSM is not a claim to be on a list we are not on. It is the documentation discipline that makes the longer route survivable: a complete CTD or ACTD dossier, registration and export history across jurisdictions, a WHO-format Certificate of a Pharmaceutical Product, and data that holds when a reviewer tests a sample independently.
We are equally clear about what we cannot supply. India's CDSCO is recorded on the WHO Maturity Level 3 listing with a scope column reading vaccines, not medicines, and on the transitional register on the same terms. Any claim that an Indian WHO-GMP certificate is automatically accepted in the FSM would be an invention. What can honestly be said is that the full route exists, that the fee schedule contemplates inspecting a site no recognised authority has inspected, and that one guideline clause reaches Maturity Level 3 authorities while its annex does not. Those are questions for the Unit, in writing.
For buyers whose volumes are small and whose freight is long, the commercial arithmetic matters as much as the regulatory one. Imported medicines attract the residual customs duty on CIF value, there is no general medicines exemption outside foreign-aid consignments, and the licensed local establishment is a legal requirement rather than a convenience. We work to that shape: consolidated shipments and shelf life planned around a long route.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Does the Federated States of Micronesia have a medicines register?
Yes. Two Acts signed on 21 June 2022 created a national Pharmaceutical Unit, an Approved Medicines List and a product registration route, and a later package supplied the forms, fees and annexes. The confusion arises because the consolidated FSM Code published online is updated only to 2001 and does not contain these chapters. Whether the Approved Medicines List itself has been published is a separate question, and we could not locate it.
Is India's CDSCO on the FSM's recognised-authority lists?
Not on any of the named lists. CDSCO appears in neither annex of recognised authorities, nor on the FSM's PIC/S table, because India is not a PIC/S participating authority. One clause of the same guideline admits authorities operating at WHO Maturity Level 3 for either medicines or vaccines, wording CDSCO satisfies, and that clause sits against the closed annex. We report the conflict rather than resolving it, and recommend a written question to the Unit.
Does the Compact of Free Association require US FDA approval?
No, not as a Compact obligation. United States law ceased to apply to the FSM in 1986, and the Compact's implementing legislation contains no medicines or FDA provision. Two things are true alongside that: US federal programmes operating in the FSM remain subject to their own US rules, and the FSM runs at least one such health programme. Whether any carries an FDA-approval or product-origin condition we could not establish, and it should be asked rather than assumed.
Can Farbe Firma import into the FSM directly?
No. The import control legislation requires the importer to be a licensed FSM Establishment and provides that a manufacturer may not be the importer of record. In practice a Micronesian licensed partner holds the import licence and commonly acts as local technical representative on the registration file. We supply the manufacturing, dossier and certification side of that partnership.
Is donor funding available for medicines in the FSM?
The layer is operative rather than empty. The Global Fund's 2026 eligibility list records the FSM as eligible for HIV and for tuberculosis, with tuberculosis burden classified high, and not eligible for malaria. Eligibility is not an allocation and not a grant, and we could not locate a current grant or its procurement channel. Treat it as worth checking with the national health department, not as confirmed demand.
Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India.
Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog
Comments